Celgene Corp (CELG)

CELG has an exciting new product in Revlimid, a tremendous pipeline and a savvy management team that is making all the right moves and will continue to grow this outstanding company

One of the fastest growing biotechs with relatively recent approval of Revlimid, which, I believe will be rapidly accepted and will have increasing indications shortly. Analysts have not fully priced in the implications of these increasing indications. Pipeline includes IMID's. Although the trailing 12 month PE is very high, this is PAST HISTORY. Company expected to grow over 100% this year, even by conservative analyst expectations. It has just entered the mid-large cap realm, has recently been added to S&P 500, has raised over one billion dollars in cash (by selling stock from it's treasury at market price to funds that needed stock to comply with ETF, mutual fund requirements as a result of being added to the S&P), to fund future research, also not reflected yet on income statements.

good products; way over sold

63

Raising eranings guidance soon

A biotech that actually has earnings!

Approval of Revlimid in EU will push earnings above analysts estimates. Growth of pipeline will become more evident in the next few years

Another pharmaceutical on a tear upward.The company profile touts a product pipeline aimed at"the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases." The Company has a portfolio of drug candidates in its product pipeline, including a pipeline of IMiDs compounds, which are a class of compounds having certain immunomodulatory and other properties."
Such immunomodulatory drugs ‘modulate’disordered immune processes caused by diseases like MS and have a corrective effect on the immune system. This is good news for what seems to be an increasing number of those suffering from a variety of illnesses affecting their immune system.

Who is going to pass up a cancer cure?

growth medical stock

Picking stocks based on holdings of a top mutual fund in my 401k.

Cancer and Psoriasis drugs.

Steady Performer

Repeatedly picked by analysts and other stock pickers to outperform. Has returned 24% for me in 4 months.

Been on a downtrend since July of 2008, yet its cancer drugs can offer strong growth prospects, and since they are potentially life-saving I can't imagine people not using them.

.

CELG, GILD and GENZ are the best biotech plays around. Wouldn't be surprised in the least if all three are bought out in the next 1-2 years.

Beaten down for a revenue miss. Who cares? Look at the growth.

target-71